GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulse Biosciences Inc (NAS:PLSE) » Definitions » Cyclically Adjusted Price-to-FCF

Pulse Biosciences (Pulse Biosciences) Cyclically Adjusted Price-to-FCF : (As of Apr. 27, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Pulse Biosciences Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pulse Biosciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Pulse Biosciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulse Biosciences Cyclically Adjusted Price-to-FCF Chart

Pulse Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pulse Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pulse Biosciences's Cyclically Adjusted Price-to-FCF

For the Medical Instruments & Supplies subindustry, Pulse Biosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulse Biosciences's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Pulse Biosciences's Cyclically Adjusted Price-to-FCF falls into.



Pulse Biosciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Pulse Biosciences's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec23 is calculated as:

For example, Pulse Biosciences's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec23 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=-0.69/129.4194*129.4194
=-0.690

Current CPI (Dec23) = 129.4194.

Pulse Biosciences Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 0.000 99.070 0.000
201512 -0.450 99.792 -0.584
201612 -0.737 101.863 -0.936
201712 -0.924 104.011 -1.150
201812 -1.415 105.998 -1.728
201912 -1.677 108.420 -2.002
202012 -1.540 109.897 -1.814
202112 -1.950 117.630 -2.145
202212 -1.397 125.222 -1.444
202312 -0.690 129.419 -0.690

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pulse Biosciences  (NAS:PLSE) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Pulse Biosciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Pulse Biosciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pulse Biosciences (Pulse Biosciences) Business Description

Traded in Other Exchanges
Address
3957 Point Eden Way, Hayward, CA, USA, 94545
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.
Executives
Robert W Duggan director, 10 percent owner 611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Kevin Patrick Danahy officer: Chief Commercial Officer 50 TEABERRY LANE, BRAINTREE MA 02184
Mitchell E. Levinson director 3957 POINT EDEN WAY, HAYWARD CA 94545
Manmeet Singh Soni director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Van Den Broek Richard director 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Maky Zanganeh director 51 ADAM WAY, ATHERTON CA 94027
Sandra A. Gardiner officer: CFO & EVP Admin. and Finance CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Shelley D Spray director C/O PULSE BIOSCIENCES, INC., 3957 POINT EDEN WAY, HAYWARD CA 94545
Laureen Debuono director
Ed Ebbers officer: EVP & GM, Dermatology 3957 POINT EDEN WAY, HAYWARD CA 94545
Kenneth A Clark director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Fogarty Thomas J M D director C/O VENTURE LAW GROUP, 2800 SAND HILL RD STE 270, MENLO PARK CA 94025
Thierry B. Thaure director 3957 POINT EDEN WAY, HAYWARD CA 94545
Robert J. Greenberg director 12744 SAN FERNANDO ROAD, BLDG. 3, SYLMAR CA 91342
Brian B Dow officer: CFO & SVP Admin. and Finance 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588

Pulse Biosciences (Pulse Biosciences) Headlines

From GuruFocus

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

By Business Wire Business Wire 05-10-2023